Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-006993
Filing Date
2025-05-08
Accepted
2025-05-08 16:30:29
Documents
69
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20250331x10q.htm   iXBRL 10-Q 1493733
2 EX-10.3 acrs-20250331xex10d3.htm EX-10.3 106888
3 EX-10.4 acrs-20250331xex10d4.htm EX-10.4 17499
4 EX-31.1 acrs-20250331xex31d1.htm EX-31.1 15490
5 EX-31.2 acrs-20250331xex31d2.htm EX-31.2 15555
6 EX-32.1 acrs-20250331xex32d1.htm EX-32.1 9426
  Complete submission text file 0001558370-25-006993.txt   7341824

Data Files

Seq Description Document Type Size
7 EX-101.SCH acrs-20250331.xsd EX-101.SCH 44557
8 EX-101.CAL acrs-20250331_cal.xml EX-101.CAL 44085
9 EX-101.DEF acrs-20250331_def.xml EX-101.DEF 186318
10 EX-101.LAB acrs-20250331_lab.xml EX-101.LAB 440863
11 EX-101.PRE acrs-20250331_pre.xml EX-101.PRE 303579
72 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20250331x10q_htm.xml XML 1384354
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 25926783
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)